Both are remarkably safe, but EVO ICL is often a safer, more stable option for patients with extreme nearsightedness or severely dry eyes. Because it does not alter corneal thickness or disrupt surface ocular nerves, it avoids the risk of inducing permanent structural weakening or worsening existing dry eye disease.